Blog

Novel ways to mitigate the toxicity associated with combination therapy for EGFR-mutant advanced NSCLC – ESMO

ESMO/LinkedIn

Mar 27, 2025, 14:29

Novel ways to mitigate the toxicity associated with combination therapy for EGFR-mutant advanced NSCLC – ESMO

ESMO – European Society for Medical Oncology shared a post on LinkedIn:

“Two studies presented at ELCC25 highlight novel ways to mitigate the toxicity associated with combination therapy for EGFR-mutant advanced NSCLC.

The ETOP AMAZE-lung phase II Clinical Trial sought to provide an alternative to amivantamab plus chemotherapy for patients after progression on osimertinib. Amivantamab, lazertinib and bevacizumab demonstrated modest yet durable efficacy with manageable toxicity.
In the COCOON trial, skin adverse events were significantly reduced using a prophylactic enhanced dermatologic regimen compared with standard dermatologic management following the initiation of first-line amivantamab plus lazertinib.

Julien MAZIERES comments on these findings in the ESMO Daily Reporter.”

Amivantamab Bevacizumab cancer chemotherapy COCOON trial EGFR ESMO ESMODailyReporter ETOP AMAZE European Society for Medical Oncology fight against cancer Global fight against cancer Julien Mazières lazertinib NSCLC OncoDaily Oncology osimertinib

USA vs Europe: Who Does Cancer Screening Better?

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action